At the recent SEC meeting for Ophthalmology held on 19th March 2025, the expert panel reviewed the proposal to conduct a ...

The green light comes on the back of the phase 3 ARCHWAY trial which showed that Susvimo was equivalent to monthly Lucentis injections at maintaining vision in patients over 40 weeks, with 98% of ...

In July 2014, the U.S. FDA approved EYLEA (aflibercept) Injection for treating diabetic macular edema (DME). Ranibizumab (Genentech) – Marketed as LUCENTIS, ranibizumab is a monoclonal antibody ...

Patients requiring frequent ranibizumab intravitreal injections for various indications as part of their routine clinical care were recruited to partake in this study. The primary goal of the ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

Lucentis' main patents are not due to expire ... intervals between dosing - an attractive proposition for patients as injections need to be administered into the eye - but has been affected ...

In this study, 4300 patients received 0.3 or 0.5 mg of ranibizumab every 3 months after the initial series of three monthly injections. After the first 3 injections the mean visual acuity improved ...

A single intravitreal injection of UBX1325 (foselutoclax ... "For example, in one trial, while ranibizumab [Lucentis] treatment resulted in a mean gain of 10 letters on the visual acuity chart ...

Intravitreal injections with anti-VEGF biological treatments ... The PDS consists of an implant body with a reservoir containing ranibizumab 100 mg/mL and a release mechanism, an extrascleral ...